These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 34461040)
1. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet; 2021 Sep; 398(10305):1053-1064. PubMed ID: 34461040 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205 [TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K; Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651 [TBL] [Abstract][Full Text] [Related]
4. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. Pinho-Gomes AC; Azevedo L; Copland E; Canoy D; Nazarzadeh M; Ramakrishnan R; Berge E; Sundström J; Kotecha D; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K; PLoS Med; 2021 Jun; 18(6):e1003599. PubMed ID: 34061831 [TBL] [Abstract][Full Text] [Related]
5. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Nazarzadeh M; Bidel Z; Canoy D; Copland E; Wamil M; Majert J; Smith Byrne K; Sundström J; Teo K; Davis BR; Chalmers J; Pepine CJ; Dehghan A; Bennett DA; Smith GD; Rahimi K; Lancet; 2021 Nov; 398(10313):1803-1810. PubMed ID: 34774144 [TBL] [Abstract][Full Text] [Related]
6. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Ettehad D; Emdin CA; Kiran A; Anderson SG; Callender T; Emberson J; Chalmers J; Rodgers A; Rahimi K Lancet; 2016 Mar; 387(10022):957-967. PubMed ID: 26724178 [TBL] [Abstract][Full Text] [Related]
7. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Xie X; Atkins E; Lv J; Bennett A; Neal B; Ninomiya T; Woodward M; MacMahon S; Turnbull F; Hillis GS; Chalmers J; Mant J; Salam A; Rahimi K; Perkovic V; Rodgers A Lancet; 2016 Jan; 387(10017):435-43. PubMed ID: 26559744 [TBL] [Abstract][Full Text] [Related]
8. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695 [TBL] [Abstract][Full Text] [Related]
9. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Law MR; Morris JK; Wald NJ BMJ; 2009 May; 338():b1665. PubMed ID: 19454737 [TBL] [Abstract][Full Text] [Related]
10. Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis. Bidel Z; Nazarzadeh M; Canoy D; Copland E; Gerdts E; Woodward M; Gupta AK; Reid CM; Cushman WC; Wachtell K; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K; Hypertension; 2023 Nov; 80(11):2293-2302. PubMed ID: 37485657 [TBL] [Abstract][Full Text] [Related]
11. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. Oikonomou EK; Spatz ES; Suchard MA; Khera R Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193 [TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S; Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765 [TBL] [Abstract][Full Text] [Related]
13. Blood pressure targets in adults with hypertension. Arguedas JA; Leiva V; Wright JM Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004349. PubMed ID: 33332584 [TBL] [Abstract][Full Text] [Related]
14. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Liu J; Li Y; Ge J; Yan X; Zhang H; Zheng X; Lu J; Li X; Gao Y; Lei L; Liu J; Li J; Lancet; 2024 Jul; 404(10449):245-255. PubMed ID: 38945140 [TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Zanchetti A; Thomopoulos C; Parati G Circ Res; 2015 Mar; 116(6):1058-73. PubMed ID: 25767290 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. He J; Ouyang N; Guo X; Sun G; Li Z; Mu J; Wang DW; Qiao L; Xing L; Ren G; Zhao C; Yang R; Yuan Z; Wang C; Shi C; Liu S; Miao W; Li G; Chen CS; Sun Y; Lancet; 2023 Mar; 401(10380):928-938. PubMed ID: 36871573 [TBL] [Abstract][Full Text] [Related]
18. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Hansson L; Zanchetti A; Carruthers SG; Dahlöf B; Elmfeldt D; Julius S; Ménard J; Rahn KH; Wedel H; Westerling S Lancet; 1998 Jun; 351(9118):1755-62. PubMed ID: 9635947 [TBL] [Abstract][Full Text] [Related]
19. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. ; Ninomiya T; Perkovic V; Turnbull F; Neal B; Barzi F; Cass A; Baigent C; Chalmers J; Li N; Woodward M; MacMahon S BMJ; 2013 Oct; 347():f5680. PubMed ID: 24092942 [TBL] [Abstract][Full Text] [Related]
20. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. Thomopoulos C; Parati G; Zanchetti A J Hypertens; 2018 Aug; 36(8):1622-1636. PubMed ID: 29847485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]